Medine.co.uk

Rewisca 50 Mg Hard Capsules

Informations for option: Rewisca 50 Mg Hard Capsules, show other option
Document: leaflet MAH BRAND_PL 24837-0062 change


Package leaflet: Information for the user

CONSILIENT HEALTH u«.

Rewisca® 25 mg hard capsules Rewisca® 50 mg hard capsules Rewisca® 75 mg hard capsules Rewisca® 100 mg hard capsules Rewisca® 1 50 mg hard capsules Rewisca® 200 mg hard capsules Rewisca® 225 mg hard capsules Rewisca® 300 mg hard capsules

pregabalin

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

•    Keep this leaflet. You may need to read it again.

•    If you have any further questions, ask your doctor or pharmacist.

•    This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

•    If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1.    What Rewisca is and what it is used for

2.    What you need to know before you take Rewisca

3.    How to take Rewisca

4.    Possible side effects

5.    How to store Rewisca

6.    Contents of the pack and other information

1. What Rewisca is and what it is used for

Rewisca belongs to a group of medicines used to treat epilepsy and Generalised Anxiety Disorder (GAD) in adults.

Epilepsy: Rewisca is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults. Your doctor will prescribe Rewisca for you to help treat your epilepsy when your current treatment is not controlling your condition. You should take Rewisca in addition to your current treatment. Rewisca is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.

Generalised Anxiety Disorder: Rewisca is used to treat Generalised Anxiety Disorder (GAD). The symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control. GAD can also cause restlessness or feeling keyed up or on edge, being easily fatigued (tired), having difficulty concentrating or mind going blank, feeling irritable, having muscle tension or sleep disturbance. This is different to the stresses and strains of everyday life.

2. What you need to know before you take Rewisca

Do not take Rewisca:

•    if you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions:

Talk to your doctor or pharmacist before taking Rewisca.

•    Some patients taking pregabalin have reported symptoms suggesting an allergic reaction.These symptoms include swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. Should you experience any of these reactions, you should contact your physician immediately.

•    pregabalin has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients. Therefore, you should be careful until you are used to any effect the medicine might have.

•    pregabalin may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. You should immediately tell your doctor if you experience any changes in your vision.

•    Some patients with diabetes who gain weight while taking pregabalin may need an alteration in their diabetic medicines.

•    There have been reports of heart failure in some patients when taking pregabalin; these patients were mostly elderly with cardiovascular conditions.

Before taking this medicine you should tell your doctor

if you have a history of heart disease.

•    There have been reports of kidney failure in some patients when taking pregabalin. If while taking Rewisca you notice decreased urination, you should tell your doctor as stopping the medicine may improve this.

•    A small number of people being treated with antiepileptics such as Rewisca have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.

•    When Rewisca is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g., constipation, blocked or paralysed bowel). Tell your doctor if you experience constipation, especially if you are prone to this problem.

•    Before taking this medicine you should tell your doctor if you have a history of alcoholism or any drug abuse or dependence. Do not take more medicine than prescribed.

•    There have been reports of convulsions when taking pregabalin or shortly after stopping pregabalin. If you experience a convulsion, contact your doctor immediately.

•    There have been reports of reduction in brain function (encephalopathy) in some patients taking pregabalin when they have other conditions. Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease.

Children and adolescents

The safety and efficacy in children and adolescents (under

18 years of age) has not been established and therefore, Rewisca should not be used in this age group.

Other medicines and Rewisca

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Rewisca and certain other medicines may influence each other (interaction). When taken with certain other medicines, Rewisca may potentiate the side effects seen with these medicines, including respiratory failure and coma. The degree of dizziness, sleepiness and decreased concentration may be increased if Rewisca is taken together with medicinal products containing:

•    Oxycodone (used as a pain-killer)

•    Lorazepam (used for treating anxiety)

•    Alcohol

Rewisca may be taken with oral contraceptives.

Rewisca with food, drink and alcohol

Rewisca capsules may be taken with or without food.

It is advised not to drink alcohol while taking Rewisca.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Rewisca should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor.

Effective contraception must be used by women of child-bearing potential.

Driving and using machines

Rewisca may cause dizziness, sleepiness and decreased concentration. You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.

3. How to take Rewisca

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Your doctor will determine what dose is appropriate for you. Rewisca is for oral use only.

Epilepsy or Generalised Anxiety Disorder:

•    Take the number of capsules as instructed by your doctor.

•    The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day.

•    Your doctor will tell you to take Rewisca either twice or three times a day. For twice a day take Rewisca once in the morning and once in the evening, at about the same time each day. For three times a day take Rewisca once in the morning, once in the afternoon and once in the evening, at about the same time each day.

If you have the impression that the effect of Rewisca is too strong or too weak, talk to your doctor or pharmacist.

If you are an elderly patient (over 65 years of age), you should take Rewisca normally except if you have problems with your kidneys. Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.

Swallow the capsule whole with water.

Continue taking Rewisca until your doctor tells you to stop.

If you take more Rewisca than you should

Call your doctor or go to the nearest hospital emergency unit immediately. Take your box of Rewisca capsules with you. You may feel sleepy, confused, agitated, or restless as a result of taking more Rewisca than you should.

If you forget to take Rewisca

It is important to take your Rewisca capsules regularly at the same time each day. If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. In that case, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten dose.

If you stop taking Rewisca

Do not stop taking Rewisca unless your doctor tells you to. If your treatment is stopped it should be done gradually over a minimum of 1 week.

After stopping long and short-term Rewisca treatment, you need to know that you may experience certain side effects. These include, trouble sleeping, headache, nausea, feeling anxious, diarrhoea, flu-like symptoms, convulsions, nervousness, depression, pain, sweating, and dizziness.

These symptoms may occur more commonly or severely if you have been taking Rewisca for a longer period of time.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you experience swollen face or tongue or if your skin turns red and starts to blister or peel you should seek immediate medical advice.

Very common (may affect more than 1 in 10 people):

•    Dizziness, drowsiness, headache.

Common (may affect up to 1 in 10 people):

•    Increased appetite.

•    Feeling of elation, confusion, disorientation, decrease in sexual interest, irritability.

•    Disturbance in attention, clumsiness, memory impairment, loss of memory, tremor, difficulty with speaking, tingling feeling, numbness, sedation, lethargy, insomnia, fatigue, feeling abnormal.

•    Blurred vision, double vision.

•    Vertigo, problems with balance, fall.

•    Dry mouth, constipation, vomiting, flatulence, diarrhoea, nausea, swollen abdomen.

•    Difficulties with erection.

•    Swelling of the body including extremities.

•    Feeling drunk, abnormal style of walking.

•    Weight gain.

•    Muscle cramp, joint pain, back pain, pain in limb.

•    Sore throat.

Uncommon (may affect up to 1 in 100 people):

•    Loss of appetite, weight loss, low blood sugar, high blood sugar.

•    Change in perception of self, restlessness, depression, agitation, mood swings, difficulty finding words, hallucinations, abnormal dreams, panic attacks, apathy, aggression, elevated mood, mental impairment, difficulty with thinking, increase in sexual interest, problems with sexual functioning including inability to achieve a sexual climax, delayed ejaculation.

•    Changes in eyesight, unusual eye movement, changes in vision including tunnel vision, flashes of light, jerky movements, reduced reflexes, increased activity, dizziness on standing, sensitive skin, loss of taste, burning sensation, tremor on movement, decreased consciousness, loss of consciousness, fainting, increased sensitivity to noise, feeling unwell.

•    Dry eyes, eye swelling, eye pain, weak eyes, watery eyes, eye irritation.

•    Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heartbeat, heart failure.

•    Flushing, hot flushes.

•    Difficulty breathing, dry nose, nasal congestion.

•    Increased saliva production, heartburn, numb around mouth.

•    Sweating, rash, chills, fever.

•    Muscle twitching, joint swelling, muscle stiffness, pain including muscle pain, neck pain.

•    Breast pain.

•    Difficulty with or painful urination, incontinence.

•    Weakness, thirst, chest tightness.

•    Changes in blood and liver test results (blood creatinine phosphokinase increased, alanine amino transferase increased, aspartate aminotransferase increased, platelet count decreased, neutropaenia, increase in blood creatinine, decrease in blood potassium).

•    Hypersensitivity, swollen face, itchiness, hives, runny nose, nose bleed, cough, snoring.

•    Painful menstrual periods.

•    Coldness of hands and feet.

Rare (may affect up to 1 in 1,000 people):

•    Abnormal sense of smell, swinging vision, altered perception of depth, visual brightness, vision loss.

•    Dilated pupils, cross eyes.

•    Cold sweat, tightness of the throat, swollen tongue.

•    Inflammation of the pancreas.

•    Difficulty in swallowing.

•    Slow or reduced movement of the body.

•    Difficulty with writing properly.

•    Increased fluid in the abdomen.

•    Fluid in the lungs

•    Convulsions

•    Changes in the recording of electrical changes (ECG) in the heart which correspond to heart rhythm disturbances

•    Muscle damage.

•    Breast discharge, abnormal breast growth, breast growth in males.

•    Interrupted menstrual periods.

•    Kidney failure, reduced urine volume, urinary retention.

•    Decrease in white blood cell count.

•    Inappropriate behaviour.

•    Allergic reactions (which may include difficulty breathing, inflammation of the eyes (keratitis) and a serious skin reaction characterized by rash, blisters, peeling skin and pain).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.aov.uk/vellowcard.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Rewisca

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date refers to the last day of that month.

Do not store above 30°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Rewisca contains

•    The active substance is pregabalin. Each hard capsule contains 25 mg, 50 mg, 75 mg, 100 mg, 150 mg,

200 mg, 225 mg or 300 mg pregabalin.

•    The other ingredients are pregelatinised starch, talc (E553b) in capsule contents.

•    The other ingredients of 25 mg hard capsules are titanium dioxide (E171), gelatin (E441), black printing ink (shellac (E904), black iron oxide (E172), N-butyl alcohol, purified water, propylene glycol (E1520), dehydrated ethanol, isopropyl alcohol, ammonium hydroxide (E527)) in capsule shell.

•    The other ingredients of 50 mg and 75 mg hard capsules are titanium dioxide (E171), gelatin (E441), yellow iron oxide (E172), black printing ink (shellac (E904), black iron oxide (E172), N-butyl alcohol, purified water, propylene glycol (E1520), dehydrated ethanol, isopropyl alcohol, ammonium hydroxide (E527)) in capsule shell.

•    The other ingredients of 100 mg hard capsules are titanium dioxide (E171), gelatin (E441), red iron oxide

(E172), white printing ink (shellac (E904), dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol (E1520), ammonium hydroxide (E527), purified water, potassium hydroxide (E525), titanium dioxide (E171)) in capsule shell.

The other ingredients of 150 mg hard capsules are titanium dioxide (E171), gelatin (E441), red iron oxide (E172), yellow iron oxide (E172), black printing ink (shellac (E904), black iron oxide (E172), N-butyl alcohol, purified water, propylene glycol (E1520), dehydrated ethanol, isopropyl alcohol, ammonium hydroxide (E527)) in capsule shell.

The other ingredients of 200 mg and 225 mg hard capsules are titanium dioxide (E171), gelatin (E441), red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172), black printing ink (shellac (E904), black iron oxide (E172), N-butyl alcohol, purified water, propylene glycol (E1520), dehydrated ethanol, isopropyl alcohol, ammonium hydroxide (E527)) in capsule shell. The other ingredients of 300 mg hard capsules are titanium dioxide (E171), gelatin (E441), red iron oxide (E172), yellow iron oxide (E172), black iron oxide (E172), white printing ink (shellac (E904), dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol (E1520), ammonium hydroxide (E527), purified water, potassium hydroxide (E525), titanium dioxide (E171)) in capsule shell.

What Rewisca looks like and contents of the pack

25 mg hard capsules: The body of the capsule is white colour, the cap of the capsule is white colour. Capsule cap is imprinted with black mark P25. The content of the capsule is white to off white powder.

50 mg hard capsules: The body of the capsule is white colour, the cap of the capsule is pale yellow colour.

Capsule cap is imprinted with black mark P50. The content of the capsule is white to off white powder.

75 mg hard capsules: The body of the capsule is brownish yellow colour, the cap of the capsule is brownish yellow colour. Capsule cap is imprinted with black mark P75. The content of the capsule is white to off white powder.

100 mg hard capsules: The body of the capsule is reddish brown colour, the cap of the capsule is reddish brown colour. Capsule cap is imprinted with white mark P100. The content of the capsule is white to off white powder.

150 mg hard capsules: The body of the capsule is white colour, the cap of the capsule is yellowish brown colour. Capsule cap is imprinted with black mark P150. The content of the capsule is white to off white powder.

200 mg hard capsules: The body of the capsule is brown colour, the cap of the capsule is brown colour. Capsule cap is imprinted with black mark P200. The content of the capsule is white to off white powder.

225 mg hard capsules: The body of the capsule is white colour, the cap of the capsule is brown colour. Capsule cap is imprinted with black mark P225. The content of the capsule is white to off white powder.

300 mg hard capsules: The body of the capsule is white colour, the cap of the capsule is dark brown colour. Capsule cap is imprinted with white mark P300. The content of the capsule is white to off white powder.

Rewisca is available in boxes of 14,21,56,70,84,100 or 112 (2x56) hard capsules in blister packs.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Consilient Health Ltd., 5th floor, Beaux Lane House, Mercer Street Lower, Dublin 2, Ireland

Manufacturer

KRKA, d. d., Novo mesto, Smarjeska cesta 6,

8501 Novo mesto, Slovenia

This leaflet was last revised in 04/2015.

P0343